Use of calixarenes associated with an antibiotic in the treatment of bacterial infections
AssigneeUniversite De Lorraine
InventorsMarion Grare, Raphaël Emmanuel Duval
Life of this patent
Estimating the term…
Abstract
A product comprising a calixarene for its use in the treatment of pathologies involving at least one bacterial strain having a resistance to at least one defined antibiotic, on patients undergoing simultaneous or sequential treatment with a given antibiotic to which said bacterial strain optionally has a resistance.
Claims13
A method of treating an infection by a bacterial strain having an acquired resistance to at least one defined antibiotic, comprising administering to a patient in need thereof an effective amount of a product, said patient undergoing simultaneous or sequential treatment by said antibiotic, the product comprising a calixarene represented by Formula I below:
- in which:
- (i) n=an integer from 4 to 16,
- (ii) m=an integer from 1 to 10,
- (iii) X is chosen from:
- a hydrogen,
- an alkyl group, the number of carbons being from 1 to 20,
- a halogen chosen from Cl, Br, I, or
- an amphiphilic group chosen from an anionic group or a cationic group.
A method of treating an infection by a bacterial strain having a natural resistance to at least one defined antibiotic, comprising administering to a patient in need thereof an effective amount of a product, said patient undergoing simultaneous or sequential treatment with said antibiotic, the product comprising a calixarene represented by Formula I below:
- in which:
- (i) n=an integer from 4 to 16,
- (ii) m=an integer from 1 to 10,
- (iii) X is chosen from:
- a hydrogen,
- an alkyl group, the number of carbons being from 1 to 20, in particular from 1 to 10,
- a halogen chosen from Cl, Br, I, or
- an amphiphilic group chosen from an anionic group or a cationic group.
A method of treating infection by at least one bacterial strain having a resistance to at least one defined antibiotic, on patients undergoing simultaneous or sequential treatment with a given antibiotic to which said bacterial strain optionally has a resistance, or pathologies involving a wild-type bacterial strain having no acquired resistance to any known antibiotic, on patients undergoing simultaneous or sequential treatment with a “given antibiotic” to which said bacterial strain has no resistance, comprising administering to a patient in need thereof an effective amount of a product comprising a calixarene represented by Formula I below:
- in which:
- (i) n=an integer from 4 to 16,
- (ii) m=an integer from 1 to 10,
- (iii) X is chosen from:
- a hydrogen,
- an alkyl group, the number of carbons being from 1 to 20,
- a halogen chosen from Cl, Br, I, or
- an amphiphilic group chosen from an anionic group or a cationic group.
Dependencies are inferred from the claim text.